If changes are planned to the manufacturing method due to environmental reasons, for example, each national drug authority that has granted a marketing authorisation must be provided with proof that the change in the method does not affect the product’s efficacy or safety, and the marketing authorisations must be updated via a variation procedure to reflect the changed manufacturing method.